Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jornay PM in ADHD and Cannabis Use Disorder
NCT07838311Phase 4Not yet recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Nov 2026
- Primary completion
- Nov 2029
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of methylphenidate hydrochloride extended-release chewable tablet in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Adult ADHD Investigator Symptom Rating Scale at 12 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
methylphenidate hydrochloride extended-release chewable tablet
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT07838311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07838311.